Abstracts tagged "Systemic sclerosis"

Abstract Number: 1586 • ACR Convergence 2024
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Matthew Wells¹, Robyn Domsic², Ami Shah³, Laura Hummers⁴, Aishwarya Anilkumar¹, Tracy Frech⁵, Ariane Herrick⁶, Christopher Denton⁷, Dinesh Khanna⁸ and John Pauling¹, ¹North Bristol NHS Trust, Bristol, United Kingdom, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Manchester, UK, Aberdeen, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Telangiectasia are permanently dilated dermal postcapillary venules and are the 2nd most common manifestation (~80%) of systemic sclerosis (SSc) after Raynaud’s phenomenon (RP). The…
Abstract Number: 1823 • ACR Convergence 2024
Identification and Prediction of Systemic Sclerosis Intrinsic Subtypes Using Semi-Supervised and Supervised Learning on Gene Expression Data of Multiple Cohorts
Zhiyun Gong¹, Rezvan Parvizi², Helen Jarnagin¹, Haobin Chen³, Madeline Morrisson⁴, Tammara Wood⁵, Monique Hinchcliff⁶ and Michael Whitfield², ¹Dartmouth College, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Dartmouth, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁵Dartmouth, Hanover, NH, ⁶Yale School of Medicine, Westport, CT
Background/Purpose: Systemic Sclerosis (SSc) is a molecularly heterogeneous disease. Distinct subtypes of patients have been identified based on gene expression in skin. In this study,…
Abstract Number: 2206 • ACR Convergence 2024
There Is No Difference in Major Organ Involvement Andantibody Pattern Between Diffuse and Limited Subtypejuvenile Onsetsystemic Scleroderma Patients
Ivan Foeldvari¹, Jens Klotsche², Kathryn Torok³, Ozgur Kasapcopur⁴, Amra Adrovic⁵, Brian Feldman⁶, Flavio Sztajnbok⁷, Jordi Anton⁸, Sindhu R. Johnson⁹, Maria Teresa Terreri¹⁰, Ana Sakamoto¹¹, Raju Khubchandani¹², Valda Stanevica¹³, Gülcan Özomay Baykal¹⁴, Dieneke Schonenberg-Meinema¹⁵, Eslam Al-Abadi¹⁶, Ekaterina Alexeeva¹⁷, Maria Katsicas¹⁸, Sujata Sawhney¹⁹, vanessa smith²⁰, Simone Appenzeller²¹, Tadey Avcin²², Mikhail Kostik²³, Thomas Lehman²⁴, Suzanne Li²⁵, Hana Malcova²⁶, edoardo marrani²⁷, Clare Pain²⁸, Anjali Patwardhan²⁹, Walter Alberto Sifuentes-Giraldo³⁰, Natalia Vasquez-Canizares³¹, Sima Abu Alsaoud³², Patricia Costa Reis³³, Hajek, Stefanie Hajek, Stefanie³⁴, Mahesh Janarthanan³⁵, Dana Nemcova³⁶, Siri Opsahl Hetlevik³⁷, Maria Jose Santos³⁸, Cristina Battagliotti³⁹, Lillemor Berntson⁴⁰, blanca e r bica⁴¹, Jürgen Brunner⁴², Liora Harel⁴³, Gerd Horneff⁴⁴, Daniela Kaiser⁴⁵, Dragana Lazarevic⁴⁶, Farzana Nuruzzaman⁴⁷, Mihaela Sparchez⁴⁸ and Nicola Helmus¹, ¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁵Cerrahpasa Medical School, Istanbul, Turkey, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷UFRJ/UERJ, SAO PAULO, Brazil, ⁸Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹University of Toronto, Toronto, Canada, ¹⁰UNIFESP, São Paulo, SP, Brazil, ¹¹Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, ¹²SRCC Childrens Hospital, Mumbai, India, ¹³Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹⁴Umraniye Training and Research Hospital, Istanbul, Turkey, ¹⁵Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁶Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ¹⁷National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ¹⁸Hospital Garrahan, Buenos Aires, Argentina, ¹⁹Sir Ganga Ram Hospital, Sector 37 noida, Uttar Pradesh, India, ²⁰Ghent University Hospital, Gent, Belgium, ²¹Unicamp, Campinas, SP, Brazil, ²²University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴Hospital for Special Surgery, New York, NY, ²⁵Hackensack University Medical Center, Hackensack, ²⁶Motol University Hospital, Prague, Czech Republic, ²⁷Dipartimento Neurofarba, Università di Firenze, Firenze, Italy, ²⁸Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom, ²⁹University of Missouri-Columbia, Department of Child Health, 404 N Keene Street, Columbia MO 65210, Columbia, ³⁰Hospital Universitario Ramon y Cajal, Madrid, Spain, ³¹Children’s Hospital at Montefiore, Bronx, NY, ³²Caritas baby Hospital, East Jerusalem, Israel, ³³Hospital de Santa Maria, Lisbon, Portugal, ³⁴Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Germany, ³⁵SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³⁶MD, Prague, Czech Republic, ³⁷Oslo University Hospital, Oslo, Norway, ³⁸Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ³⁹Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ⁴⁰Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ⁴¹UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ⁴²Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ⁴³Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Petach Tikva, HaMerkaz, Israel, ⁴⁴Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁴⁵Childrens Hospital Lucerne, Lucerne, Switzerland, ⁴⁶Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, ⁴⁷Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁸Emergency Clinical Hospital for Children, Cluj-Napoca, Romania
Background/Purpose: In adult systemic sclerosis they are significant differences in clinical presentation of diffuse and limited subtype. In juvenile systemic sclerosis (jSSc) are the differences less…
Abstract Number: 2467 • ACR Convergence 2024
Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Ismael Gonzalez⁴, Ignacio Gonzalez Fernandez⁵, Carolina Díez Morrondo⁵, Carolina Alvarez Castro⁶, Paula Perez Garcia⁵, Jose Ordas Martínez⁵, Pedro Baenas Gonzalez⁵ and elvira Diez álvarez⁵, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, León, Spain, ⁵Complejo Asistencial Universitario de Leon, Leon, ⁶Complejo Asistencial Universitario de Leon, Leon, Spain
Background/Purpose: Immunosenescence refers to the gradual deterioration of the immune system associated with aging, leading to an increased incidence of infections, cancer, and autoimmune diseases.…
Abstract Number: 0405 • ACR Convergence 2023
Clinical Features of Anti-Th/To Antibodies-positive Systemic Sclerosis Patients: A Single-center Retrospective Study
Ko Fujii, Motoki Horii, Natsumi Fushida, Tomoyuki Ikeda, Yasuhito Hamaguchi and Takashi Matsushita, Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa Ishikawa, Japan
Background/Purpose: Anti-Th/To antibodies (Abs) have been reported in patients with systemic sclerosis (SSc). The presence of anti-Th/To Abs is detected in 2-5% of SSc cases…
Abstract Number: 0626 • ACR Convergence 2023
Clinical Features of Anti-hUBF Antibodies-positive Patients: A Single-center Retrospective Study
Natsumi Fushida, Motoki Horii, Kie Mizumaki, Natsuki Numata, Yasuhito Hamaguchi and Takashi Matsushita, Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa Ishikawa, Japan
Background/Purpose: Anti-human upstream-binding factor (hUBF) antibodies (Abs) have been reported predominantly in patients with connective tissue diseases (CTDs) but have also been reported in non-CTDs…
Abstract Number: 0648 • ACR Convergence 2023
Incidence and Prevalence of Malnutrition and Its Impact on Mortality in the Multicentre Singapore Systemic Sclerosis Cohort
Bochao Jiang¹, Ennaliza Salazar², Seyed Ehsan Saffari³, Gim Gee Teng⁴, Xin Rong Lim⁵, Sue-Ann Ng², Amelia Santosa⁶, Cassandra Hong² and Andrea Hsiu Ling Low⁷, ¹Ministry of Health Holdings, Singapura, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³Center for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore, ⁴Alexandra Hospital, Department of Medicine, Division of Rheumatology, National University Health System, Singapore, Singapore, ⁵Tan Tock Seng Hospital, Singapore, Singapore, ⁶Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, ⁷Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Gastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc), and may lead to malnutrition that adversely affects quality of life, morbidity and…
Abstract Number: 0669 • ACR Convergence 2023
Optical Coherence Tomography Angiography in Systemic Sclerosis: Correlations with Morphological and Functional Peripheral Microvascular Status
Carlo Alberto Cutolo¹, Elvis Hysa², Andrea Cere³, Paola Toma¹, Tommaso Cannavacciuolo¹, Chiara Toma¹, Serena Balito⁴, Veronica Gerli⁴, Alberto Sulli³, Vanessa Smith⁵, Carlo Enrico Traverso¹, Massimo Nicolò¹ and Maurizio Cutolo⁶, ¹Ophthalmology Clinic DiNOGMI, IRCCS Ophthalmology Unit San Martino Polyclinic, University of Genoa, Genoa, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, ³Laboratory of Experimental Rheumatology and Academic Division of Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Italy - IRCCS San Martino Polyclinic, Genoa, Italy, ⁵Ghent University Hospital, Gent, Belgium, ⁶Laboratory of Experimental Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy
Background/Purpose: Systemic sclerosis (SSc) is a rare and complex autoimmune disease featured by a progressive microvascular damage. The involvement of the ocular microvasculature has been…
Abstract Number: 0943 • ACR Convergence 2023
Attenuation of Fibroblast Activation and Fibrosis by Adropin in a Hedgehog-Dependent Manner
Minrui Liang and Joerg Distler, Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
Background/Purpose: Adropin is a secretory protein encoded by the energy homeostasis - associated (ENHO) gene. Emerging evidence indicate its role in metabolism and energy homeostasis,…
Abstract Number: 1216 • ACR Convergence 2023
“I Call It Zombie Hands and Feet, That’s Actually How I Found out I Had This Disease”: Disease Symptoms and Treatment Side Effects in a Diverse Sample of Patients with Early Limited Cutaneous and Diffuse Cutaneous Systemic Sclerosis
Chelsea Perschon¹, Emilie Jaeger¹, George Greene¹, Alain Lescoat², Yen Chen³, Susan Murphy³, Sara Shaunfield¹, David Cella¹ and Dinesh Khanna³, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²University Rennes, Rennes, France, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune rheumatic disease with heterogeneous manifestations, including common symptoms such as pain, fatigue, dyspnea, and Raynaud's phenomenon. It…
Abstract Number: 1663 • ACR Convergence 2023
Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells
Kimberly Lakin¹, Robert Spiera², Yaxia Zhang¹, David Oliver¹, Aliza Bloostein¹, Hiranmayi Ravichandran³, Niroshana Anandasabapathy³, Franck Barrat¹, Jessica Gordon¹ and Dana Orange⁴, ¹Hospital for Special Surgery, New York, NY, ²Hosptial for Special Surgery, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴The Rockefeller University, New York, NY
Background/Purpose: We have previously shown that skin fibroblast activation is related to clinical severity and resolves with improvement in diffuse systemic sclerosis (dcSSc). The immune…
Abstract Number: 2356 • ACR Convergence 2023
A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis
Emily Morris, Rezvan Parvizi, Patricia Pioli and Michael Whitfield, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by inflammation and fibrosis. Treatment with mycophenolate mofetil (MMF), an inhibitor of lymphocyte…
Abstract Number: 2598 • ACR Convergence 2023
6 Months-follow up Data of Systemic Sclerosis Patients Treated with CD 19 Targeting CAR-T Cells
Christina Bergmann¹, Fabian Müller², Janina Auth³, Jule Taubmann⁴, Michael Aigner⁵, Dagmar Werner⁶, Andreas Wirsching⁷, Johannes Knitza⁸, Hermina Györfi⁹, Jörg Distler¹⁰, Andreas Mackensen⁵ and Georg Schett¹¹, ¹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen, Medicine 3, Erlangen, Germany, ⁴Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁶FAU Erlangen-Nürnberg, Erlangen, Germany, ⁷University Hospital Erlangen, Department of Internal Medicine 3, Erlangen, Germany, ⁸Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁹Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁰Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: CD19-targeting CAR-T-cells showed remarkable improvements in autoimmune diseases including refractory lupus erythematodes (1,2) and inflammatory myopathy (3). Moreover, first data of a patient with…
Abstract Number: 0478 • ACR Convergence 2023
The Long-term Neurodevelopmental Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-reported Questionnaire by the Mothers and Nneuropsychiatric Evaluations of the Children
Maria Grazia Lazzaroni¹, Eleonora Pedretti¹, Liala Moschetti¹, Marzia Bendoni², Lucrezia Visconti², Anna Molinaro², Cecilia Nalli³, Franco Franceschini³, Paolo Airò¹, Jessica Galli², Elisa Fazzi², Angela Tincani⁴ and Laura Andreoli⁵, ¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ²Unit of Child and Adolescent Neuropsychiatry, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Gussago, Italy, ⁵University of Brescia, Brescia, Italy
Background/Purpose: The long-term neuropsychiatric (NP) outcome of children born to mothers affected by autoimmune diseases (AIDs) represents a controversial topic, with few studies1-3 reporting a…
Abstract Number: 0627 • ACR Convergence 2023
Clinical Significance of Anti-Ro/SSA Antibodies in Patients with Systemic Sclerosis: A Study from the EUSTAR Database
Blaz Burja¹, Marouane Boubaya², Patricia Carreira³, Christina Bergmann⁴, Lidia P Ananieva⁵, Gabriela Riemekasten⁶, Okada Masado⁷, Jeska de Vries-Bouwstra⁸, Edoardo Rosato⁹, Marie-Elise Truchetet¹⁰, Nicoletta Del Papa¹¹, Antonella Marcoccia¹², FABIOLA ATZENI¹³, Tim Schmeiser¹⁴, Madelon Vonk¹⁵, Francesco Del Galdo¹⁶, Oliver Distler¹⁷ and Muriel Elhai¹⁸, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Department of Clinical Research, CHU Avicenne, APHP, Bobigny, France, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Department Internal Medicine, University Hospital Erlangen, Germany, Erlangen, Germany, ⁵V.A. Nasonova Research Institute Of Rheumatology Russian Federation, Moscow, Russia, ⁶University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ⁷St.Luke's International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, ¹⁰Bordeaux University Hospital, Bordeaux, France, ¹¹Scleroderma Clinic, UOC Reumatologia Clinica, ASST G. Pini-CTO, Milano, Italy, ¹²Centro Di Riferimento Interdisciplinare Per La Sclerosi Sistemica, Rome, Italy, ¹³Rheumatology Unit, Univerity of Messina, Messina, Italy, ¹⁴Krankenhaus St. Josef, Wuppertal-Elberfeld, Germany, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁶University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland
Background/Purpose: Despite the progress in understanding the patient heterogeneity in systemic sclerosis (SSc) based on SSc-specific antibodies, better risk stratification is needed. SSc non-specific antibodies…

« Previous Page
1
…
7
8
9
10
11
…
46
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].